Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences (GILD) disclosed an insider transaction by Chief Commercial Officer Johanna Mercier. On 10/15/2025, she sold 3,000 shares of common stock at $118.08 per share (transaction code S). After the sale, she beneficially owned 110,193 shares, held directly.
The filing states the trade was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.
Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.
Gilead Sciences, Inc. has entered into settlement agreements to resolve patent litigation over its HIV treatment Biktarvy with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. These companies had sought U.S. approval to sell generic versions of Biktarvy.
Under the agreements, which include standard acceleration provisions, no generic entry is expected in the United States before April 1, 2036 for Biktarvy tablets containing bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg. Gilead also reiterates that these statements are forward-looking and subject to risks such as intellectual property challenges, litigation outcomes and regulatory changes.
Daniel P. O'Day, Chairman & CEO of Gilead Sciences (GILD), reported sales of common stock on 09/29/2025 under a pre-established Rule 10b5-1 trading plan adopted February 28, 2025. The Form 4 shows two sale transactions: 8,039 shares sold at prices reported in a range around $110.97–$111.92 and 1,961 shares sold at prices reported in a range around $112.00–$112.55. After these transactions the reporting person beneficially owned 591,203 shares. The filing was submitted under Section 16 and executed by power of attorney. The disclosure states that full per-price breakdowns are available on request.
Form 144 filing by an insider of Gilead Sciences (GILD) reporting proposed and recent sales of common stock. The notice shows a proposed sale of 10,000 shares to be executed through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $1,116,564.00. The shares were originally acquired as restricted stock on 03/01/2020. The filing also discloses three completed sales by the same person, DANIEL O'DAY, of 10,000 shares each on 06/30/2025, 07/28/2025, and 08/28/2025 for gross proceeds of $1,104,483.00, $1,139,369.00, and $1,136,300.00, respectively. The filing lists 1,240,806,916 shares outstanding for the class and identifies NASDAQ as the exchange.
Erin Burkhart, SVP, Controllership at Gilead Sciences (GILD), was granted 8,890 restricted stock units (RSUs) on 09/22/2025. Each RSU represents the contingent right to receive one share of common stock. The RSUs follow a four-year vesting schedule: 25% vests on the first anniversary of the grant date, with the remainder vesting at 6.25% each quarter thereafter until fully vested. Following the reported grant, Ms. Burkhart beneficially owns 8,890 shares subject to vesting, held directly. The Form 4 was filed by one reporting person and signed under power of attorney on 09/23/2025.
Erin E. Burkhart, identified as Senior Vice President, Controllership, filed an Initial Statement on Form 3 reporting her relationship to Gilead Sciences, Inc. (GILD). The event date requiring the statement is 09/22/2025. The filing discloses that no securities are beneficially owned by the reporting person as of the filing. The form indicates it was signed on behalf of Ms. Burkhart by Edward S. Son under power of attorney on 09/23/2025. This is a routine Section 16 initial disclosure showing officer status and no current ownership in the issuer.
Gilead Sciences insider sale reported on Form 4: Johanna Mercier, Chief Commercial Officer, disposed of 3,000 shares of GILD common stock on 09/15/2025 at a price of $113.57 per share under a pre-established Rule 10b5-1 trading plan adopted February 20, 2025. Following the transaction Mercier beneficially owns 113,193 shares. The Form 4 was signed by Edward S. Son by power of attorney on 09/16/2025. The filing documents a single non-derivative sale and includes the Rule 10b5-1 disclosure indicating the trade was executed pursuant to an established plan.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported a sale of 2,500 shares of Gilead common stock on 09/15/2025 at a price of $113.57 per share, reducing his beneficial holdings to 159,555 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the transaction was prearranged. The Form 4 was signed by a power of attorney on behalf of Mr. Dickinson on 09/16/2025. No derivative transactions or other types of securities are reported in this filing.
Gilead Sciences (GILD) Form 144 notice for proposed and recent insider sales. The filing shows a proposed sale of 2,500 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,925 and lists 1,240,806,916 shares outstanding. The filer, identified in the sales history as Andrew Dickinson, sold 2,500 shares on 06/16/2025 for $275,425, 2,500 shares on 07/15/2025 for $277,575, and 2,500 shares on 08/15/2025 for $296,325, totaling 7,500 shares sold in the past three months. Acquisition records show the securities were restricted stock acquired on 03/10/2022 (1,981 shares) and 03/10/2024 (519 shares). The filer certifies no undisclosed material adverse information and references Rule 10b5-1 language.